Skyepharma ended 2015 with a flurry of positive news. The partnering deal with Mundipharma for SKP-2076, Pacira’s announcement of a resolution achieved with the FDA on Exparel coupled with an encouraging FY15 pre-close update marks a good start for 2016. Skyepharma has entered into a feasibility and option agreement for SKP-2076 with Mundipharma, the partner of choice in our view, and the timely announcement could ensure seamless development once SKP-2076 feasibility studies complete by mid-2016. Meanwhile, the FDA has formally rescinded a warning letter issued to Pacira on US Exparel marketing and, importantly, also broadened the Exparel label significantly.
